Pediatric Hematology/Oncology and ImmunopathologyPediatric Hematology/Oncology and ImmunopathologyВопросы гематологии/онкологии и иммунопатологии в педиатрии1726-17082414-9314Fund Doctors, Innovations, Science for Children49210.24287/j.492РЕЗОЛЮЦИЯРезолюция Совета экспертов «Препараты фактора свертывания VIII с пролонгированным периодом полувыведения (FVIII EHL) и их роль в дальнейшем улучшении результатов терапии пациентов с гемофилией А»Редакционнаястатья
Russian Federation
210420212011601612004202120042021Copyright ©; 2021, «D. Rogachev NMRCPHOI»Copyright ©; 2021, ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России2021«D. Rogachev NMRCPHOI»ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава Россииhttps://creativecommons.org/licenses/by/4.0https://hemoncim.com/jour/article/view/492

18 ноября 2020 г. Совет экспертов обсудил ряд вопросов, касающихся применения новых препаратов фактора свертывания крови VIII с пролонгированным периодом полувыведения. В частности, были рассмотрены результаты клинических исследований эффективности и безопасности применения препарата руриоктоког альфа пэгол у пациентов с гемофилией А.

1. Srivastava A., Santagostino E., Dougall A., Kitchen S., Sutherland M., Pipe S.W., et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia 2020; 26 Suppl 6: 1–158. DOI: 10.1111/hae.14046Srivastava A., Santagostino E., Dougall A., Kitchen S., Sutherland M., Pipe S.W., et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia 2020; 26 Suppl 6: 1–158. DOI: 10.1111/hae.140462. Bjorkman S. Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective. Haemophilia 2003; 9 Suppl 1: 101–8; discussion 9–10.Bjorkman S. Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective. Haemophilia 2003; 9 Suppl 1: 101–8; discussion 9–10.3. Bjorkman S., Berntorp E. Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. Clin Pharmacokinet 2001; 40 (11): 815– 32. DOI: 10.2165/00003088-200140110-00003Bjorkman S., Berntorp E. Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. Clin Pharmacokinet 2001; 40 (11): 815– 32. DOI: 10.2165/00003088-200140110-000034. Bjorkman S., Folkesson A., Jonsson S. Pharmacokinetics and dose requirements of factor VIII over the age range 3–74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A. Eur J Clin Pharmacol 2009; 65 (10): 989–98. DOI: 10.1007/s00228-009-0676-xBjorkman S., Folkesson A., Jonsson S. Pharmacokinetics and dose requirements of factor VIII over the age range 3–74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A. Eur J Clin Pharmacol 2009; 65 (10): 989–98. DOI: 10.1007/s00228-009-0676-x5. Manco-Johnson M.J., Abshire T.C., Shapiro A.D., Riske B., Hacker M.R., Kilcoyne R., et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357 (6): 535–44. DOI: 10.1056/NEJMoa067659Manco-Johnson M.J., Abshire T.C., Shapiro A.D., Riske B., Hacker M.R., Kilcoyne R., et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357 (6): 535–44. DOI: 10.1056/NEJMoa0676596. Valentino L.A., Mamonov V., Hellmann A., Quon D.V., Chybicka A., Schroth P., et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. J Thromb Haemost 2012; 10 (3): 359–67. DOI: 10.1111/j.1538-7836.2011.04611.xValentino L.A., Mamonov V., Hellmann A., Quon D.V., Chybicka A., Schroth P., et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. J Thromb Haemost 2012; 10 (3): 359–67. DOI: 10.1111/j.1538-7836.2011.04611.x7. Mahlangu J., Young G., Hermans C., Blanchette V., Berntorp E., Santagostino E. Defi ning extended half-life rFVIII-A critical review of the evidence. Haemophilia 2018; 24 (3): 348–58. DOI: 10.1111/hae.13438Mahlangu J., Young G., Hermans C., Blanchette V., Berntorp E., Santagostino E. Defi ning extended half-life rFVIII-A critical review of the evidence. Haemophilia 2018; 24 (3): 348–58. DOI: 10.1111/hae.134388. Turecek P.L., Bossard M.J., Graninger M., Gritsch H., Höllriegl W., Kaliwoda М., et al. BAX 855, PEGylated rFVIII product with prolonged half-life. Development, functional and structural characterisation. Hamostaseologie 2012; 32 Suppl 1: S29–38.Turecek P.L., Bossard M.J., Graninger M., Gritsch H., Höllriegl W., Kaliwoda М., et al. BAX 855, PEGylated rFVIII product with prolonged half-life. Development, functional and structural characterisation. Hamostaseologie 2012; 32 Suppl 1: S29–38.9. Harris J.M., Chess R.B. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2003; 2 (3): 214–21. DOI: 10.1038/nrd1033Harris J.M., Chess R.B. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2003; 2 (3): 214–21. DOI: 10.1038/nrd103310. Turecek P.L., Romeder-Finger S., Apostol C., Bauer A., Crocker-Buqué A., Burger D.A., et al. A world-wide survey and field study in clinical haemostasis laboratories to evaluate FVIII:C activity assay variability of ADYNOVATE and OBIZUR in comparison with ADVATE. Haemophilia 2016; 22 (6): 957–65. DOI: 10.1111/hae.13001Turecek P.L., Romeder-Finger S., Apostol C., Bauer A., Crocker-Buqué A., Burger D.A., et al. A world-wide survey and field study in clinical haemostasis laboratories to evaluate FVIII:C activity assay variability of ADYNOVATE and OBIZUR in comparison with ADVATE. Haemophilia 2016; 22 (6): 957–65. DOI: 10.1111/hae.1300111. Chowdary P., Mullins E.S., Konkle B.A., McGuinn C., Park Y.S., Stasyshyn O., et al. Long-term safety and efficacy results from the phase 3b, open-label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A. Haemophilia 2020; 26: e168–78. DOI: 10.1111/hae.14052Chowdary P., Mullins E.S., Konkle B.A., McGuinn C., Park Y.S., Stasyshyn O., et al. Long-term safety and efficacy results from the phase 3b, open-label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A. Haemophilia 2020; 26: e168–78. DOI: 10.1111/hae.1405212. Klamroth R., Windyga J., Radulescu V., Collins P.W., Stasyshyn O., Ibrahim H.M., et al. Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: Results from the phase 3 PROPEL study. Blood 2020. DOI: 10.1182/blood.2020005673Klamroth R., Windyga J., Radulescu V., Collins P.W., Stasyshyn O., Ibrahim H.M., et al. Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: Results from the phase 3 PROPEL study. Blood 2020. DOI: 10.1182/blood.202000567313. Konkle B.A., Stasyshyn O., Chowdary P., Bevan D.H., Mant T., Shima M., et al. Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. Blood 2015; 126 (9): 1078–85. DOI: 10.1182/blood-2015-03-630897Konkle B.A., Stasyshyn O., Chowdary P., Bevan D.H., Mant T., Shima M., et al. Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. Blood 2015; 126 (9): 1078–85. DOI: 10.1182/blood-2015-03-63089714. Mullins E.S., Stasyshyn O., Alvarez-Roman M.T., Osman D., Liesner R., Engl W., et al. Extended half-life pegylated, full-length recombinant factor VIII for prophylaxis in children with severe haemophilia A. Haemophilia 2017; 23 (2): 238–46. DOI: 10.1111/hae.13119Mullins E.S., Stasyshyn O., Alvarez-Roman M.T., Osman D., Liesner R., Engl W., et al. Extended half-life pegylated, full-length recombinant factor VIII for prophylaxis in children with severe haemophilia A. Haemophilia 2017; 23 (2): 238–46. DOI: 10.1111/hae.13119